Announcements
- Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
- Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
- Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
- Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
- Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
- Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
- Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
- Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
- Vericel to Present at the Stephens Annual Investment Conference
More ▼
Key statistics
On Monday, Vericel Corp (ATQP:FRA) closed at 44.00, -9.84% below its 52-week high of 48.80, set on Apr 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 44.00 |
---|---|
High | 44.00 |
Low | 44.00 |
Bid | 46.00 |
Offer | 46.40 |
Previous close | 43.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 48.60m |
Free float | 48.15m |
P/E (TTM) | 5,057.53 |
Market cap | 2.35bn USD |
EPS (TTM) | 0.0096 USD |
Data delayed at least 15 minutes, as of May 20 2024 07:04 BST.
More ▼